Assessment and monitoring of biologic drug adverse events in patients with psoriasis
Tessa Hanley, Marc Handford, Dawn Lavery, Zenas ZN Yiu Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, UKBackground: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.Objective: The aim of this pap...
Guardado en:
Autores principales: | Hanley T, Handford M, Lavery D, Yiu ZZN |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f31746f798074739988f79dc90dc4482 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy
por: Agozzino M, et al.
Publicado: (2017) -
Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents
por: Aimilios Lallas, et al.
Publicado: (2016) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan M, et al.
Publicado: (2021) -
Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes KE, et al.
Publicado: (2016) -
Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability
por: Abrouk M, et al.
Publicado: (2016)